Level Biotechnology (3118) - Total Assets
Based on the latest financial reports, Level Biotechnology (3118) holds total assets worth NT$799.85 Million TWD (≈ $25.20 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Level Biotechnology - Total Assets Trend (2017–2024)
This chart illustrates how Level Biotechnology's total assets have evolved over time, based on quarterly financial data. Also see 3118 market cap overview for the company's overall valuation and market capitalisation.
Level Biotechnology - Asset Composition Analysis
Current Asset Composition (December 2024)
Level Biotechnology's total assets of NT$799.85 Million consist of 58.5% current assets and 41.5% non-current assets. Review Level Biotechnology balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 30.6% |
| Accounts Receivable | NT$112.09 Million | 13.6% |
| Inventory | NT$98.09 Million | 11.9% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Level Biotechnology's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 3118 live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Level Biotechnology's current assets represent 58.5% of total assets in 2024, a decrease from 74.6% in 2017.
- Cash Position: Cash and equivalents constituted 30.6% of total assets in 2024, down from 43.8% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 13.6% of total assets.
Level Biotechnology Competitors by Total Assets
Key competitors of Level Biotechnology based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Vaxcyte Inc
NASDAQ:PCVX
|
USA | $3.14 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $1.11 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.16 Billion |
Level Biotechnology - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.93 | 2.65 | 2.71 |
| Quick Ratio | 1.53 | 2.23 | 2.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$210.42 Million | NT$397.96 Million | NT$383.95 Million |
Level Biotechnology - Advanced Valuation Insights
This section examines the relationship between Level Biotechnology's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.89 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | 0.5% |
| Total Assets | NT$827.11 Million |
| Market Capitalization | $32.10 Million USD |
Valuation Analysis
Below Book Valuation: The market values Level Biotechnology's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Level Biotechnology's assets grew by 0.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Level Biotechnology (2017–2024)
The table below shows the annual total assets of Level Biotechnology from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$827.11 Million ≈ $26.06 Million |
+0.54% |
| 2023-12-31 | NT$822.67 Million ≈ $25.92 Million |
+1.25% |
| 2022-12-31 | NT$812.53 Million ≈ $25.60 Million |
+3.16% |
| 2021-12-31 | NT$787.62 Million ≈ $24.81 Million |
+1.89% |
| 2020-12-31 | NT$772.99 Million ≈ $24.35 Million |
+3.04% |
| 2019-12-31 | NT$750.18 Million ≈ $23.63 Million |
+10.26% |
| 2018-12-31 | NT$680.39 Million ≈ $21.44 Million |
-7.09% |
| 2017-12-31 | NT$732.31 Million ≈ $23.07 Million |
-- |
About Level Biotechnology
Level Biotechnology Inc. engages in marketing and distributing cell culture, immunology, and molecular biology products in Taiwan. It markets and distributes biomedical precision equipment. The company also provides services in the areas of mammalian and genetic toxicology, pharmacology, biocompatibility, and model animal production. In addition, it offers preclinical research services to the bio… Read more